- Report
- February 2024
- 110 Pages
Global
From €4609EUR$4,750USD£3,975GBP
- Report
- January 2024
- 200 Pages
Global
From €4027EUR$4,150USD£3,473GBP
- Report
- January 2021
- 600 Pages
United States
From €2717EUR$2,800USD£2,343GBP
- Report
- October 2022
- 80 Pages
Global
From €5773EUR$5,950USD£4,979GBP
- Report
- November 2021
- 40 Pages
China
From €2523EUR$2,600USD£2,176GBP
- Drug Pipelines
- January 2018
- 19 Pages
Global
From €9703EUR$10,000USD£8,368GBP
- Report
- April 2023
- 129 Pages
Global
€4852EUR$5,000USD£4,184GBP
Casodex is a drug used to treat prostate cancer. It is a non-steroidal anti-androgen (NSAA) that works by blocking the action of androgens, hormones that can cause the growth of prostate cancer cells. Casodex is usually used in combination with other drugs, such as luteinizing hormone-releasing hormone (LHRH) agonists, to treat advanced prostate cancer. It is also used to treat metastatic prostate cancer, which has spread to other parts of the body. Casodex is available in both oral and injectable forms.
The Casodex market is highly competitive, with a number of companies offering similar products. These companies include AstraZeneca, Bayer, Merck, Pfizer, and Sanofi. Each company offers its own unique formulation of Casodex, with different dosages and delivery methods. Additionally, some companies offer generic versions of the drug, which can be more affordable for patients. Show Less Read more
